Pedersen Martin H, Bjerregaard Niels Christian, Hvid-Jensen Frederik, Kjaer Daniel W
Department of Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, Denmark.
Surg Endosc. 2025 Jun 16. doi: 10.1007/s00464-025-11832-z.
Achalasia is a rare esophageal motility disorder that in many cases can be treated effectively with Peroral Endoscopic Myotomy (POEM). However, long-term outcomes regarding clinical efficacy, patient satisfaction, and the prevalence of post-POEM gastro-esophageal reflux disease (GERD) remains elusive and thus require further investigation.
This retrospective cohort study followed 63 patients treated for achalasia with POEM. Clinical success (Eckardt-score ≤ 3, and no subsequent treatments), GERD prevalence (GerdQ-score ≥ 8), and patient satisfaction were assessed via medical record reviews and telephone interviews. Statistical analyses identified risk factors for treatment failure, lower levels of satisfaction, and GERD.
At a median follow-up of 10 years, clinical success was 74%. The average Eckardt-score improved from 7,6 pre-POEM to 2,16 (p < 0.0001). The majority of treatment failures occurred within three months post-POEM, with no new failures after 5 years. GERD symptoms were reported by 33% of patients. Patient satisfaction was high with 91% reporting to be satisfied or very satisfied. Treatment-naïve patients had higher success rates (85%) compared to those with prior Heller's myotomy (40%, p < 0.0001). No other risk factors for clinical failure were found. RePOEM showed superior outcomes for salvage treatment compared to balloon dilation, botulinum toxin injections, and Heller's myotomy.
POEM has a good and lasting efficacy at a median follow-up of 10 years. Clinical failure was not observed beyond 5 years post-POEM. The majority of patients were satisfied with POEM at follow-up. Symptomatic GERD was a highly experienced side effect at follow-up, however, not associated with lower levels of satisfaction.
贲门失弛缓症是一种罕见的食管动力障碍性疾病,在许多情况下可通过经口内镜下肌切开术(POEM)有效治疗。然而,关于临床疗效、患者满意度以及POEM术后胃食管反流病(GERD)患病率的长期结果仍不明确,因此需要进一步研究。
这项回顾性队列研究追踪了63例接受POEM治疗贲门失弛缓症的患者。通过病历回顾和电话访谈评估临床成功率( Eckardt评分≤3,且无需后续治疗)、GERD患病率(GerdQ评分≥8)和患者满意度。统计分析确定了治疗失败、满意度较低和GERD的危险因素。
在中位随访10年时,临床成功率为74%。Eckardt评分的平均值从POEM术前的7.6提高到2.16(p<0.0001)。大多数治疗失败发生在POEM术后三个月内,5年后没有新的失败病例。33%的患者报告有GERD症状。患者满意度较高,91%的患者报告满意或非常满意。与先前接受过Heller肌切开术的患者(40%,p<0.0001)相比,未经治疗的患者成功率更高(85%)。未发现其他临床失败的危险因素。与球囊扩张、肉毒杆菌毒素注射和Heller肌切开术相比,再次POEM在挽救治疗方面显示出更好的效果。
在中位随访10年时,POEM具有良好且持久的疗效。POEM术后5年以上未观察到临床失败。大多数患者在随访时对POEM满意。有症状的GERD是随访中常见的副作用,然而,与较低的满意度无关。